Rezolute, Inc., was incorporated in Delaware in 2010 and re-incorporated in Nevada in June 2021. The Company is an advanced rare disease company focused on significantly improving the prognosis of patients with hypoglycemia caused by hyperinsulinemia (" HI "). The company's main clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by many forms of hyperinsulinemia. 

Rezolute shares surge 10.55% after-hours after sharing Phase 3 sunRIZE study insights and expanded access program findings.

RZLT News